• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

荷载紫杉醇介孔二氧化硅纳米粒的制备及体外性能

张雪, 苏志桂, 薛玲静, 张灿

张雪, 苏志桂, 薛玲静, 张灿. 荷载紫杉醇介孔二氧化硅纳米粒的制备及体外性能[J]. 中国药科大学学报, 2015, 46(6): 653-658. DOI: 10.11665/j.issn.1000-5048.20150603
引用本文: 张雪, 苏志桂, 薛玲静, 张灿. 荷载紫杉醇介孔二氧化硅纳米粒的制备及体外性能[J]. 中国药科大学学报, 2015, 46(6): 653-658. DOI: 10.11665/j.issn.1000-5048.20150603
ZHANG Xue, SU Zhigui, XUE Lingjing, ZHANG Can. Preparation and in vitro properties of paclitaxel-loaded mesoporous silica nanoparticle[J]. Journal of China Pharmaceutical University, 2015, 46(6): 653-658. DOI: 10.11665/j.issn.1000-5048.20150603
Citation: ZHANG Xue, SU Zhigui, XUE Lingjing, ZHANG Can. Preparation and in vitro properties of paclitaxel-loaded mesoporous silica nanoparticle[J]. Journal of China Pharmaceutical University, 2015, 46(6): 653-658. DOI: 10.11665/j.issn.1000-5048.20150603

荷载紫杉醇介孔二氧化硅纳米粒的制备及体外性能

Preparation and in vitro properties of paclitaxel-loaded mesoporous silica nanoparticle

  • 摘要: 介孔二氧化硅纳米粒(mesoporous silica nanoparticle,MSN)作为药物载体已成为纳米给药系统研究的热点。以无序孔道的MSN为载体,以溶剂吸附法负载化疗药物紫杉醇(PTX),从而制备得到PTX@MSN。考察了PTX@MSN的理化性质、药物体外释放行为和体外抗肿瘤活性等特性。研究结果表明,PTX@MSN载药量为(23.76±1.14)%,在水性介质中分散良好,粒径约为250 nm,电位为-(8.01±1.81)mV。PTX@MSN具有药物缓释特性,24 h后PTX累积释放率为(23.62±2.15)%。细胞毒性结果显示,空白MSN生物安全性良好,而PTX@MSN组对人肝癌HepG2细胞的杀伤作用较市售Taxol组强。本研究为MSN递送抗肿瘤药物提供一定的理论与应用基础。
    Abstract: Mesoporous silica nanoparticle as drug carrier has become the new research focus in the field of nano-drug delivery system in recent years. In this study, paclitaxel-loaded msesoporous silica nanoparticle(PTX@MSN)was manufactured by the solvent adsorption. In vitro studies revealed that PTX@MSN was well dispersed in aqueous medium with particle size of 250 nm, the potential of -(8. 01±1. 81)mV and drug loading efficiency of(23. 76±1. 14)%. PTX@MSN showed the sustained-release characteristics with the cumulative PTX of release(23. 62±2. 15)% at 24 h. In additions, the cytotoxicity investigation indicated that blank MSNs were biocompatible while PTX@MSN group showed improved in vitro anti-tumor activity against HepG2 cell when compared with Taxol group. In conclusion, MSN is a promising platform to build drug delivery systems for tumor therapy.
  • [1] Vallet-Regi M,Ramila A.A new property of MCM-41:drug delivery system[J].Chem Mater,2001,13(4):308-311.
    [2] Wang M,Zhang J,Yuan Z,et al.Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles[J].J Biomed Nanotechnol,2012(6),8:624-632.
    [3] Wu S,Hung Y,Mou C.Mesoporous silica nanoparticles as nanocarriers[J].Chem Comm,2011,47(21):9972-9985.
    [4] Tang FQ,Li LL,Chen D.Mesoporous silica nanoparticles:synthesis,biocompatibility and drug delivery[J].Adv Mater,2012,24(12):1504-1534.
    [5] Slowing II,Vivero-Escoto JL,Wu CW,et al.Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers[J].Adv Drug Deliv Rev,2008,60(11):1278-1288.
    [6] Jia LJ,Shen JY,Li ZY,et al.Successfully tailoring the pore size of mesoporous silica nanoparticles:exploitation of delivery systems for poorly water-soluble drugs[J].Int J Pharm,2012,439(1/2):81-91.
    [7] Jia LJ, Shen JY, Li ZY, et al. In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes[J].Int J Pharm,2013,445(1):12-19.
    [8] Li WT,Wang L,Zhang C.Influence of surface characteristics on hepatocellular carcinoma cells uptake of nano-liposomes[J].J China Pharm Univ(中国药科大学学报),2013,44(3):244-248.
    [9] Wu X, Wang ZY, Zhu D, et al. pH and thermo dual-stimuli-responsive drug carrier based on mesoporous silica nanoparticles encapsulated in a copolymer-lipid bilayer[J].Appl Mat Interfaces ACS,2013,5(21):10895-10903.
    [10] Qu D,Lin HJ,Zhang N,et al.In vitro evaluation an novel midified chitosan for targeted antitumor drug[J].Carbohyd Polym,2012,92(1):545-554.
    [11] Zheng O,Wan NH,Zhou MM,et al.Effect of pH on the dispersion characteristics of fumed silica[J].Chin J Appl Chem(应用化学),2011,28(12):1448-1452.
    [12] Yu T, Malugin A, Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity[J].ACS Nano,2011,5(7):5717-5728.
    [13] Lyu FF,Cao JN,Zhang J,et al.Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2014,73(11):1173-1179.
计量
  • 文章访问数:  1333
  • HTML全文浏览量:  3
  • PDF下载量:  2138
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭